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ABSTRACT 
Background: Although chronic breathlessness is common in life-limiting illnesses, validated, 
feasible instruments to measure functional impact of the symptom in this population are 
scarce. We aimed to validate the Dyspnea Exertion Scale (DES) compared with the modified 
Medical Research Council (mMRC) breathlessness scale for test-retest reliability, construct 
validity and responsiveness in people with life-limiting illness. 
Methods: A total of 188 participants, 66% male, with chronic breathlessness mostly (70%) 
due to chronic pulmonary disease (COPD) self-reported evening scores of mMRC, DES, 
Numerical rating scale (NRS) and Eastern Cooperative Oncology Group (ECOG) over 9 days.  
Results: 44% (n=81) scored the highest score on mMRC indicating a ceiling effect not seen 
with DES. Both scales had moderate to good test-retest agreement (89% DES; 84% mMRC; 
p<0.001 for both). Analyses for construct validity showed that higher DES and mMRC scores 
were correlated with higher NRS breathlessness intensity scores and ECOG scores throughout 
the 9 days. In longitudinal analyses, DES (DES  r =0.30, p<0001) was more responsive to 
change in NRS score over nine days than the mMRC (mMRC r=0.16, p=0.03).  
Conclusion: Compared to mMRC, DES had comparable or better measurement properties in 
terms of test-retest reliability and construct validity and could be used as a discriminative tool 
in this population, but both scales are to insensitive to change to be used as an outcome in 
clinical trials.  
Keywords: Breathlessness, measurement, Medical Research Council breathlessness scale, 
Dyspnea Exertion Scale (DES), mMRC, DES, validation. 
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INTRODUCTION  
Chronic breathlessness is common and causes major suffering in patients with life-limiting 
illness.[1] It is associated with increased morbidity and mortality, including worse quality of 
life and increased dependency on health services.[2, 3] Nearly all people with life-limiting 
cardiac or respiratory disease will experience chronic breathlessness late in their disease 
trajectory, becoming persistent and triggered by minimal exertion, or present even at rest.[1, 
3-5] 
There are few validated simple unidimensional instruments which measure the functional 
impact in people with chronic breathlessness useful and feasible for categorizing patients and 
for prognosis purposes.[1, 6] Whilst measures of exercise-induced breathlessness may be 
applicable in the early, more stable phases of pulmonary disease, arguably these are less 
relevant in later stages when breathlessness is triggered by minimal movement or even at rest 
without an obvious precipitant. [6] Existing measures are mostly disease-specific (cancer, 
COPD or motor neuron disease) and designed for use in a research, rather than clinical, 
setting. [7] Routine clinical assessment of chronic breathlessness is important to identify and 
manage this often-neglected symptom.[7, 8] 
The modified Medical Research Council (mMRC) breathlessness scale is a widely used 
measure of the presence and severity of breathlessness in relation to physical activities (Table 
1).[2, 9-12] It was developed in the 1950’s with the main purpose to categorize disability due 
to breathlessness in research and is still the most used instrument across both clinical and 
research settings.  The mMRC scale is discriminative but to insensitive to change to be used 
as outcome in clinical trials, it is recommended by international guidelines for categorizing 
the severity of COPD [13] and strongly predicts increased hospitalization, reduced quality of 
life and mortality, being a better predictor of death than the degree of airflow limitation.[14, 
15] 
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However, the mMRC scale is only weakly associated with physiological and functional 
measures of impairment, and is poorly responsive to change over time and in relation to 
therapy, perhaps because it only has five categories.[16, 17] In patients with severe illness 
there might be a risk of a ceiling effect (defined as >15% of respondents selecting the highest 
score category [18]) as many patients, despite varying levels of symptom and disability, are 
likely to be in the worst category.[19] 
The Dyspnea Exertion Scale (DES; Table 1) was developed from the mMRC scale for use in 
people with advanced cancer.[20] DES may offer better face validity than mMRC for people 
with severe COPD who have breathlessness at rest or with minimal exertion.[19] DES was 
presented within an MD-thesis [20] and has never been published as a peer reviewed paper or 
compared formally against the mMRC. The relative merits of mMRC and DES for measuring 
exertion-related chronic breathlessness due to life-limiting illness is unknown.[6, 19] 
The aim of this study was to compare DES with mMRC in terms of test-retest reliability, 
construct validity and responsiveness for measuring chronic breathlessness in people with 
life-limiting illnesses.  
 
METHODS 
Study design and population  
This was a secondary analysis of a multi-center, double-blind, randomized controlled trial of 
ambulatory oxygen compared with medical air for one week in people with chronic 
breathlessness.[21]  
Participants (n=239) were recruited between April 2006 and March 2008 from outpatient 
pulmonary, palliative care, and primary care clinics in Australia (five sites), USA (two sites) 
5 
 
and in the UK (two sites). Only data from the Australian participants were available for this 
analysis (n=188). 
Eligible participants were: aged ≥ 18 years; with a life-limiting illness who did not qualify for 
long term oxygen therapy; partial pressure of oxygen in arterial blood (PaO2) > 7.3 kPa 
breathing ambient air; mMRC ≥3 at screening despite optimal disease management; life-
expectancy longer than one month; and stable medication for at least the previous week. 
Exclusion criteria included current smoking; a respiratory or cardiac event in the previous 
seven days; anemia (hemoglobin < 100g/L); partial pressure of carbon dioxide in arterial 
blood <8 PaCO2> 6.7kPa; or cognitive impairment (Mini Mental State examination score < 24 
points).[22]  
 
Assessments 
Baseline was defined as Day 1 (two days before randomisation) and assessments continued to 
Day 9 thus including seven treatment days.  
Evening values of DES (using the question ‘What is your breathlessness like right now?’) 
mMRC (‘What is your best exertional performance today?’), and a 11-point numerical rating 
scale (NRS) (‘How is your breathlessness right now’) between 0 (not breathless at all) and 10 
(breathlessness as bad as you can imagine) was recorded by the study participant for each of 
the 9 days.[10]  
Functional status was assessed by research personnel on Days 1, 3 and 9 using Eastern 
Cooperative Oncology Group (ECOG).[23, 24] ECOG was categorized as: asymptomatic (0), 
symptomatic but ambulatory (1), symptomatic, <50% in bed during the day (2), 
symptomatic,> 50% in bed but not bedbound (3), and bedbound (4).[23] 
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Ethical considerations 
The study was approved by the Southern Adelaide Health Service Human Research Ethics 
Committee as well as local research and ethics committees or institutional review boards of 
all participating sites. All participants provided written informed consent. 
 
Statistical analyses 
Baseline patient characteristics were summarized using mean with standard deviation (SD) 
and median with range or interquartile range (IQR) for continuous variables with normal and 
skewed distribution, respectively. Categorical variables were expressed as frequencies and 
percentages.  
The measurement properties of DES and mMRC were evaluated in concordance with 
international guidelines for the evaluation of patient reported outcomes measure.[25] Test-
retest reliability of DES and mMRC were assessed using ratings on day 1 and 2 (before 
randomisation). Ratings were cross-tabulated and test-retest reliability was assessed using the 
weighted kappa statistics with linear weights. A kappa value of 0.7 or above is considered 
good.[18, 25]Construct validity (meaning the correlation with other relevant measures) was 
assessed using Kendall’s tau B rank correlation coefficient, looking at associations between 
DES and mMRC values and NRS and ECOG scores, all from day 1. Responsiveness was 
assessed by the regression slope of NRS and DES over time from Day 1 through 9 for each 
individual participant, accounting for correlations. Patients with recorded ratings for fewer 
than half the days were excluded (n=11) from the responsiveness analyses. Statistical 
significance was defined as two-sided p-value < 0.05. Statistical analyses were conducted 
using the software packages Stata, version 14.1 (StataCorp LP; College Station, TX). 
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RESULTS 
Patient characteristics 
Table 2 shows baseline characteristics of the 188 included participants; 66% were males and 
the most common cause of breathlessness was COPD (70 %). Nearly 40% of the participants 
had previously been prescribed long term oxygen therapy. The mean DES and mMRC scores 
at baseline were 2.3 and 2.9, respectively (Table 2).  
 
Score distribution and reliability 
The distribution of mMRC on DES scores and their inter-relation is shown in Figure 1. Out of 
all respondents, 44% scored the highest category (4) on mMRC, indicating a ceiling effect in 
this setting, while only 6% scored the highest category (5) on DES. Most of the responses 
categorized as mMRC 2-4 scored DES at category 2. Nine individuals (6.6%) scored the 
highest category on mMRC and the lowest (1) on DES at the same time (Figure 1).  
The relationship between both scales and the NRS rating is shown in figures 2a and b. Test-
retest agreement was moderate to good for both scales (89% DES; 84% mMRC; p <0.0001) 
with kappa values of approximately 0.6 for both scales (Table 3, e-figure 2a-b).   
 
Construct validity 
Both DES and mMRC were correlated with NRS breathlessness intensity scores and ECOG 
scores (Table 4). All correlations were highly statistically significant (DES and mMRC; 
p<0.0001, DES and NRS; p<0.0001, mMRC and NRS; p=0.0468, DES and ECOG; p=0.003 
mMRC and ECOG; p<0.0001).  The NRS was correlated more strongly with the DES 
(Kendall Tau-B=0.32) than the mMRC (Kendall’s Tau-B=0.12).  
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Responsiveness 
The change in DES and NRS scores over the nine-day period is shown in Figure 3. The 
change scores for both scales were approximately normally distributed.  The mean change is 
less than zero in each case, indicating an overall tendency for both breathlessness scores to 
decrease over the study period.  A change in DES was associated with change in NRS, r=0.3 
(p<0.0001) (Figure 3a). The mMRC also showed a statistically significant association with 
change in NRS, r=0.16 (p=0.03) (Figure 3). 
 
DISCUSSION 
In this first validation study in people with life-limiting illnesses, DES, compared to mMRC, 
had similar or slightly better test-retest reliability and construct validity. Both scales were 
relatively unresponsive to change. The need of an instrument more adapted to this setting than 
mMRC is highlighted by that 44% of the participants were in the highest mMRC category. 
DES differentiated the group of patients with mMRC 4 and increasing DES scores were more 
closely correlated to increasing breathlessness intensity (NRS scores) compared with 
increasing mMRC scores. This study also identified a potential problem with DES as the 
comparative distribution shows that most mMRC values 3-5 equate to DES 2 values, 
indicating that the category may be too broad. Furthermore, the response options 2-5 are not 
mutually exclusive. The participant may both be breathless when walking around the house as 
well as when getting out of bed and the category 2 might be the first one that applies to most 
respondents. A further problem with measurements of this kind is the fact that the scales are 
used differently in different settings. There is a need for standardization on this issue, further 
highlighted by the fact that nine individuals rated the highest score on mMRC and the lowest 
on DES at the same time. Compared to mMRC, DES was more responsive to changes in 
breathlessness intensity (NRS scores) but correlations were weak. Although DES may be 
9 
 
more useful for description and discriminating patient populations and was more responsive 
than mMRC, it may have insufficient responsiveness to be used as endpoints in clinical trials. 
 MMRC has been shown to have a prognostic value for mortality in COPD, exceeding that of 
the level of airflow limitation.[15] Given the similarities in phrasing between mMRC and 
DES and the comparable or better reliability and construct validity, the associations with 
prognosis and clinical outcomes might be similar or better for DES than for mMRC in people 
with life-limiting illness. Whenever possible the multidimensional aspects of breathlessness 
should be assessed [26] [27] 
Strengths of this study include the use of a quality data set with a large cohort of patients with 
life-limiting illness and chronic breathlessness in a randomized controlled trial, with 
standardized, longitudinal collection of clinically relevant data over nine days.  
Potential limitations were that the eligibility criteria of the randomized controlled trial may 
limit the generalizability to all patients with life-limiting disease, which should be evaluated 
in further studies in this setting. The questions were not asked precisely the same which might 
affect the results, probably in the direction of underestimating mMRC. Full understanding of 
the impacts of chronic breathlessness may need a multi-dimensional measurement in research, 
but in clinical practice among people with life-limiting illness it might be more useful to focus 
on simple and unidimensional measurements.  
This study has important implications for practice and research. For clinicians, DES is a 
discriminative tool that could be used for assessing symptom prevalence and functional 
impact of breathlessness to describe and select patient populations in clinical care and 
research. Both scales are insufficiently responsive to be used as an outcome measure of 
therapy but DES had better score distribution in severe illness with less ceiling effect.  Further 
research should focus on the optimal questioning and standardizing the use to ensure a better 
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distribution. In the light of the problems showed with both scales, perhaps a combination of 
the two scales could prove useful to give a better distribution and differentiation of patients.  
Conclusion 
Compared to mMRC, DES had comparable or better measurement properties in terms of test-
retest reliability and construct validity and could be used as a discriminative tool in this 
population, but both scales are to insensitive to change to be used as an outcome in clinical 
trials.  
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TABLES 
 
Table 1. Dyspnea Exertion Scale (DES) and Medical Research Council (mMRC) 
breathlessness scale 
Dyspnea Exertion Scale (DES) Medical Research Council (mMRC) scale 
1 = I am able to walk at my own pace on the 
level without getting out of breath 
0 = Not troubled by breathlessness, except 
with strenuous exercise. 
2 = I become breathless if I walk around the 
house or on the hospital ward on the level at 
my own pace 
1 = Troubled by shortness of breath when 
hurrying on the level or walking up a slight 
hill 
2 =Breathless or has to stop for breath when 
walking at own pace on the level 
3 = Stops for breath after walking about 100 
yards (90m) or after a few minutes on the 
level 
3 = I become breathless if I move around in 
bed or get out of bed 4 = Breathless when dressing or undressing 
4 = I become breathless on talking  5 = I am breathless at rest 
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Table 2. Baseline characteristics 
 
SD= standard deviation, COPD = Chronic Obstructive Pulmonary Disease, PaO2= partial pressure of oxygen in arterial 
blood, PaC02= partial pressure of carbon dioxide in arterial blood, DES = Dyspnea Exertion Scale, mMRC = modified 
Medical Research Council, ECOG = Eastern Cooperative Oncology Group (ECOG)  
 
  
Variable All (n=188) 
Age, mean (SD) 73.4 (10.1) 
Gender (%)  
Male 124 (66) 
Missing 1 (0.5) 
Causes of breathlessness (%)  
   COPD 131(70) 
   Primary lung cancer 24(13) 
   Other causes 36(19) 
PaO2, kPa Mean (SD) 10.1 (1.6) 
PaCO2,kPa Mean (SD) 5.2 (0.5) 
Oxygen treatment (%) 38.8 (4.4) 
DES (n=177) (%)  
   1 33 (19) 
   2 86 (49) 
   3 27 (15) 
   4 25 (14) 
   5 6 (3) 
   Missing 9 
mMRC(n=182) (%)  
   1 25 (14) 
   2 47 (26) 
   3 29 (16) 
   4 81 (44) 
   Missing 6 
ECOG(n=181) (%)  
   1 52 (28) 
   2 80 (42) 
   3 49 (26) 
   Missing 7 
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Table 3: Test-retest reliability of DES and mMRC.  
 Agreement Expected 
agreement 
Kappa P-value 
DES 89.12% 72.94% 0.598 <0.0001 
mMRC 83.70% 59.01% 0.602 <0.0001 
DES= Dyspnea Exertion Scale, mMRC= modified Medical Research Council, Agreement and expected agreement for ratings 
of breathlessness between two days. Test-retest reliability assessed using the weighted kappa statistics with linear weights. 
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Table 4: Associations between DES and mMRC values and NRS and ECOG scores  
Comparison Correlation between the scores (Kendall’s tau B) P - value 
DES vs mMRC 0.32 <0.0001 
DES vs NRS 0.32 <0.0001 
mMRC vs NRS   0.12 0.0468 
DES vs ECOG 0.23 0.0003 
mMRC vs ECOG 0.30 <0.0001 
Associations were measured using Kendall’s tau B ranging from 1 (all rankings are the same) to -1 (all rankings are the 
reverse of the other).  DES = Dyspnea Exertion Scale, mMRC =modified Medical Research Council, NRS = numerical rating 
scale, ECOG = Eastern Cooperative Oncology Group (ECOG) 
  
17 
 
FIGURES 
 
Figure 1:  Distribution of modified Medical Research Council (mMRC) scores vs. Dyspnea 
Exertion Scale (DES) scores  
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Figure 2a: Boxplot showing the distribution of Dyspnea Exertion Scale (DES) per Numerical 
Rating Scale score (NRS).  
 
Figure 2b: Boxplot showing the distribution of modified Medical Research Council (mMRC) 
per Numerical Rating Scale score (NRS).  
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Figure 3a: Change in Dyspnea Exertion Scale (DES) plotted against change in Numerical 
Rating Scale (NRS) of breathlessness. 
 
Figure 3b: Change in modified Medical Research Council (mMRC) plotted against change in 
Numerical Rating Scale (NRS) of breathlessness. 
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